Penumbra (PEN) | Stock Overview & Key Data
Penumbra Performance Comparison
Stock Range
Today's Range
Low: $251.29
High: $258.12
on August 21, 2025
52 Week Range
Low: $184.80
High: $310.00
on September 16, 2024
on February 19, 2025
All-Time High: $348.67 on June 26, 2023
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$9.9B
EPS
3.77
P/E Ratio (TTM)
67.16
Forward P/E
66.98
P/B Ratio
7.63
PEG Ratio
-0.39
Div. Yield
N/A
ROE
12.03%
Beta
0.402
Debt to Equity
17.04
Financial Highlights
Profitability
Gross Margin
65.99%
Operating Margin
12.03%
Profit Margin
11.54%
Returns and Earnings
Return on Assets (TTM)
6.20%
Return on Equity (TTM)
12.03%
EBITDA
$193.7M
Net Income (TTM)
$147.7M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$33.26
Quarterly Revenue Growth (YoY)
13.40%
Quarterly Earnings Growth (YoY)
13.38%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Penumbra PEN | 9.87B Mid-cap | -0.73% | 9.84% | -7.03% | -13.82% | 4.74% | 19.63% | 51.55% | 13.77% |
| Abbott Laboratories ABT | 229.31B Mega-cap | 2.10% | 6.09% | -0.79% | -2.16% | 16.36% | 17.14% | 29.54% | 19.14% |
| Boston Scientific BSX | 153.73B Large-cap | 1.02% | 1.38% | 0.54% | 0.69% | 17.71% | 32.89% | 159.65% | 156.42% |
| Globus Medical GMED | 8.26B Mid-cap | 0.80% | 16.59% | 2.06% | -24.64% | -26.07% | -16.03% | 0.27% | 7.14% |
| Masimo MASI | 7.97B Mid-cap | -5.02% | -7.02% | -3.45% | -15.13% | -14.43% | 20.26% | -4.97% | -34.37% |
| Bio-Rad Laboratories BIO | 7.59B Mid-cap | -0.76% | 16.70% | 25.02% | 1.77% | -12.61% | -9.50% | -42.45% | -42.86% |
Ownership & Short Interest
Insider Ownership
3.60%
Institutional Ownership
93.75%
Shares Short
2M
Short Ratio
3.07
Short % of Shares Outstanding
5.43%
Average 10-Day Volume
334K
Average 90-Day Volume
478K
Penumbra Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Penumbra would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is PEN's 52-week high and low?
- In the last 52 weeks, Penumbra reached a high of $310.00 (on February 19, 2025) and a low of $184.80 (on September 16, 2024).
- What is the market cap and P/E ratio for PEN?
- Curious about Penumbra's size and valuation? Its market capitalization stands at 9.87B. When it comes to valuation, the P/E ratio (trailing twelve months) is 67.16, and the forward P/E (looking ahead) is 66.98.
- Does PEN pay dividends? If so, what's the yield?
- As for dividends, Penumbra isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Penumbra's main competitors or similar companies to consider before investing?
When looking at Penumbra, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abbott Laboratories
ABT229.31B Healthcare Medical Devices 17.14% 29.54% Boston Scientific
BSX153.73B Healthcare Medical Devices 32.89% 159.65% Globus Medical
GMED8.26B Healthcare Medical Devices -16.03% 0.27% Masimo
MASI7.97B Healthcare Medical Devices 20.26% -4.97% Bio-Rad Laboratories
BIO7.59B Healthcare Medical Devices -9.50% -42.45% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Penumbra Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Penumbra's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 12.03%, the Debt to Equity ratio from the most recent quarter is 17.04, and its Gross Profit Margin stands at 65.99%.
- What is the recent revenue and earnings growth for PEN?
- Looking at Penumbra's growth, its revenue over the trailing twelve months (TTM) was $1B. Compared to the same quarter last year (YoY), quarterly revenue grew by 13.40%, and quarterly earnings saw a YoY growth of 13.38%.
- How much of PEN stock is held by insiders and institutions?
- Wondering who owns Penumbra stock? Company insiders (like executives and directors) hold about 3.60% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 93.75%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.